Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This is a randomised, placebo controlled study to evaluate the efficacy of a 3 week treatment
period with Circadin® 2 mg in shortening sleep latency in patients with primary insomnia aged
18-80 with melatonin deficiency.